SOF/VEL/VOX 在既往 DAA 失败丙肝患者中的真实世界疗效与安全性
本研究纳入意大利北部 27 个中心 2018 年 5–10 月连续接受 SOF/VEL/VOX 治疗的 179 例既往 DAA 失败 HCV 患者,评估真实世界疗效与安全性。意向性分析 SVR12 为 91%(162/179),符合方案分析为 96%(162/169);肝硬化(p=0.005)和肝细胞癌(p=0.02)是治疗失败的唯一预测因素。最常见不良事件为乏力(6%)、高胆红素血症(6%)和贫血(4%)。
要点
- 既往 DAA 失败 HCV 患者接受 SOF/VEL/VOX 12 周,符合方案分析 SVR12 达 96%。
- 肝硬化(p=0.005)和肝细胞癌(p=0.02)是治疗失败的唯一预测因素。
- 最常见不良事件为乏力(6%)、高胆红素血症(6%)和贫血(4%)。
核心结论
- 在真实世界 setting 中,SOF/VEL/VOX 是既往 DAA 失败 HCV 患者有效且安全的再治疗方案。
研究设计与样本
- 研究纳入意大利北部 27 个中心 2018 年 5–10 月连续接受 SOF/VEL/VOX 治疗的 179 例既往 DAA 失败 HCV 患者。
- 肝纤维化分期通过肝脏硬度测定诊断:F3 为 >10 kPa,F4 为 >13 kPa。
- SVR 定义为治疗结束后 4 周(SVR4)或 12 周(SVR12)HCV-RNA 检测不到。
主要发现
- 患者中位年龄 57(18–88)岁,男性 74%,中位 HCV-RNA 1,081,817(482–25,590,000)IU/ml。
- 纤维化分期 F0–F2 占 32%,F3 占 21%,F4 占 44%;HCV 基因型 1 型占 58%(1b 33%、1a 24%、1nc 1%)、2 型 10%、3 型 23%、4 型 9%;82% 患者携带 NS3、NS5A 或 NS5B 区域耐药相关替代。
- 所有患者接受 SOF/VEL/VOX 治疗 12 周,22% 的治疗方案加用了利巴韦林。
- 治疗第 4 周 74% 患者 HCV-RNA 检测不到,第 12 周达 99%。
- 意向性分析 162/179(91%)患者、符合方案分析 162/169(96%)患者获得 SVR12;治疗失败包括 6 例复发和 1 例病毒学无应答。
关键数值与推荐
- SVR12:意向性分析 91%(162/179),符合方案分析 96%(162/169)。
- 治疗第 4 周 HCV-RNA 检测不到者 74%,第 12 周 99%。
- 肝硬化(p=0.005)和肝细胞癌(p=0.02)是治疗失败的预测因素。
- 不良事件发生率:乏力 6%、高胆红素血症 6%、贫血 4%。
临床怎么用
- 对于既往 DAA 方案失败的 HCV 患者,可考虑使用 SOF/VEL/VOX 12 周再治疗,合并肝硬化或肝细胞癌者需关注治疗失败风险。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Sofosbuvir/velpatasivr/voxilaprevir (SOF/VEL/VOX) is approved for retreatment of patients with HCV and a previous failure on direct-acting antivirals (DAAs), however real-life data are limited. The aim of this study was to assess the effectiveness and safety of SOF/VEL/VOX in a real-life setting. METHODS: All consecutive patients with HCV receiving SOF/VEL/VOX between May-October 2018 in 27 centers in Northern Italy were enrolled. Bridging fibrosis (F3) and cirrhosis (F4) were diagnosed by liver stiffness measurement: >10 and >13 kPa respectively. Sustained virological response (SVR) was defined as undetectable HCV-RNA 4 (SVR4) or 12 (SVR12) weeks after the end-of-treatment. RESULTS: A total of 179 patients were included: median age 57 (18-88) years, 74% males, median HCV-RNA 1,081,817 (482-25,590,000) IU/ml. Fibrosis stage was F0-F2 in 32%, F3 in 21%, F4 in 44%. HCV genotype was 1 in 58% (1b 33%, 1a 24%, 1nc 1%), 2 in 10%, 3 in 23% and 4 in 9%; 82% of patients carried resistance-associated substitutions in the NS3, NS5A or NS5B regions. Patients received SOF/VEL/VOX for 12 weeks, ribavirin was added in 22% of treatment schedules. Undetectable HCV-RNA was achieved by 74% of patients at week 4 and by 99% at week 12. Overall, 162/179 (91%) patients by intention to treat analysis and 162/169 (96%) by per protocol analysis achieved SVR12, respectively; treatment failures included 6 relapsers and 1 virological non-responder. Cirrhosis (p = 0.005) and hepatocellular carcinoma (p = 0.02) were the only predictors of treatment failure. Most frequent adverse events included fatigue (6%), hyperbilirubinemia (6%) and anemia (4%). CONCLUSIONS: SOF/VEL/VOX is an effective and safe retreatment for patients with HCV who have failed on a previous DAA course in a real-life setting. LAY SUMMARY: This is the largest European real-life study evaluating effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) in a large cohort of consecutive patients with hepatitis C virus infection and a prior direct-acting antiviral failure, who were treated within the NAVIGATORE Lombardia and Veneto Networks, in Italy. This study demonstrated excellent effectiveness (98% and 96% sustained virological response rates at week 4 and 12, respectively) and an optimal safety profile of SOF/VEL/VOX. Cirrhosis and hepatocellular carcinoma onset were the only features associated with treatment failure.
引用
- Degasperi E, Spinetti A, Lombardi A, et al. Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure. J Hepatol. 2019. PMID: 31433303. doi:10.1016/j.jhep.2019.07.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。